Literature DB >> 23393156

Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.

Patrick J Schultheis1, Sheila M Fleming, Amy K Clippinger, Jada Lewis, Taiji Tsunemi, Benoit Giasson, Dennis W Dickson, Joseph R Mazzulli, Mark E Bardgett, Kristi L Haik, Osunde Ekhator, Anil Kumar Chava, John Howard, Matt Gannon, Elizabeth Hoffman, Yinhuai Chen, Vikram Prasad, Stephen C Linn, Rafael J Tamargo, Wendy Westbroek, Ellen Sidransky, Dimitri Krainc, Gary E Shull.   

Abstract

Mutations in ATP13A2 (PARK9), encoding a lysosomal P-type ATPase, are associated with both Kufor-Rakeb syndrome (KRS) and neuronal ceroid lipofuscinosis (NCL). KRS has recently been classified as a rare genetic form of Parkinson's disease (PD), whereas NCL is a lysosomal storage disorder. Although the transport activity of ATP13A2 has not been defined, in vitro studies show that its loss compromises lysosomal function, which in turn is thought to cause neuronal degeneration. To understand the role of ATP13A2 dysfunction in disease, we disrupted its gene in mice. Atp13a2(-/-) and Atp13a2(+/+) mice were tested behaviorally to assess sensorimotor and cognitive function at multiple ages. In the brain, lipofuscin accumulation, α-synuclein aggregation and dopaminergic pathology were measured. Behaviorally, Atp13a2(-/-) mice displayed late-onset sensorimotor deficits. Accelerated deposition of autofluorescent storage material (lipofuscin) was observed in the cerebellum and in neurons of the hippocampus and the cortex of Atp13a2(-/-) mice. Immunoblot analysis showed increased insoluble α-synuclein in the hippocampus, but not in the cortex or cerebellum. There was no change in the number of dopaminergic neurons in the substantia nigra or in striatal dopamine levels in aged Atp13a2(-/-) mice. These results show that the loss of Atp13a2 causes sensorimotor impairments, α-synuclein accumulation as occurs in PD and related synucleinopathies, and accumulation of lipofuscin deposits characteristic of NCL, thus providing the first direct demonstration that null mutations in Atp13a2 can cause pathological features of both diseases in the same organism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23393156      PMCID: PMC3633373          DOI: 10.1093/hmg/ddt057

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  80 in total

1.  Subfield variations in hippocampal processing-components of a spatial navigation system.

Authors:  Matthew Hartley; Neill Taylor; John Taylor
Journal:  Neural Netw       Date:  2005 Jun-Jul

2.  Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats.

Authors:  T Schallert; I Q Whishaw; V D Ramirez; P Teitelbaum
Journal:  Science       Date:  1978-03-31       Impact factor: 47.728

3.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

4.  Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype.

Authors:  Norbert Brüggemann; Johann Hagenah; Kathrin Reetz; Alexander Schmidt; Meike Kasten; Inga Buchmann; Susanne Eckerle; Manfred Bähre; Alexander Münchau; Ana Djarmati; Joyce van der Vegt; Hartwig Siebner; Ferdinand Binkofski; Alfredo Ramirez; Maria I Behrens; Christine Klein
Journal:  Arch Neurol       Date:  2010-11

5.  Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.

Authors:  Jason P Covy; Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2012-07-30       Impact factor: 4.164

6.  Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET.

Authors:  A G De Volder; S Cirelli; T de Barsy; J M Brucher; A Bol; C Michel; A M Goffinet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

7.  Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.

Authors:  Ramune Reliene; Sheila M Fleming; Marie-Françoise Chesselet; Robert H Schiestl
Journal:  Food Chem Toxicol       Date:  2007-08-29       Impact factor: 6.023

8.  Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.

Authors:  Jose Bras; Alain Verloes; Susanne A Schneider; Sara E Mole; Rita J Guerreiro
Journal:  Hum Mol Genet       Date:  2012-03-02       Impact factor: 6.150

9.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

10.  Cod1p/Spf1p is a P-type ATPase involved in ER function and Ca2+ homeostasis.

Authors:  Stephen R Cronin; Rajini Rao; Randolph Y Hampton
Journal:  J Cell Biol       Date:  2002-06-10       Impact factor: 10.539

View more
  62 in total

1.  ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.

Authors:  Taiji Tsunemi; Kana Hamada; Dimitri Krainc
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

2.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

Review 3.  The neuropathology of neurodegeneration with brain iron accumulation.

Authors:  Michael C Kruer
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

4.  Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls.

Authors:  Breann T Colter; Helen Frances Garber; Sheila M Fleming; Jocelyn Phillips Fowler; Gregory D Harding; Molly Kromme Hooven; Amy Ashworth Howes; Smitha Krishnan Infante; Anna L Lang; Melinda Curran MacDougall; Melinda Stegman; Kelsey Rae Taylor; Christine Perdan Curran
Journal:  Neurotoxicology       Date:  2018-03       Impact factor: 4.294

5.  Thioredoxin-interacting protein induced α-synuclein accumulation via inhibition of autophagic flux: Implications for Parkinson's disease.

Authors:  Cun-Jin Su; Yu Feng; Teng-Teng Liu; Xu Liu; Jun-Jie Bao; Ai-Ming Shi; Duan-Min Hu; Tong Liu; Yun-Li Yu
Journal:  CNS Neurosci Ther       Date:  2017-07-29       Impact factor: 5.243

6.  Loss of Mitochondrial Function Impairs Lysosomes.

Authors:  Julie Demers-Lamarche; Gérald Guillebaud; Mouna Tlili; Kiran Todkar; Noémie Bélanger; Martine Grondin; Angela P Nguyen; Jennifer Michel; Marc Germain
Journal:  J Biol Chem       Date:  2016-03-17       Impact factor: 5.157

Review 7.  Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions.

Authors:  Martin L Katz; Eline Rustad; Grace O Robinson; Rebecca E H Whiting; Jeffrey T Student; Joan R Coates; Kristina Narfstrom
Journal:  Neurobiol Dis       Date:  2017-08-30       Impact factor: 5.996

Review 8.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

Review 9.  Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease.

Authors:  Daniel J Colacurcio; Ralph A Nixon
Journal:  Ageing Res Rev       Date:  2016-05-16       Impact factor: 10.895

10.  Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.

Authors:  Joseph R Mazzulli; Friederike Zunke; Taiji Tsunemi; Nicholas J Toker; Sohee Jeon; Lena F Burbulla; Samarjit Patnaik; Ellen Sidransky; Juan J Marugan; Carolyn M Sue; Dimitri Krainc
Journal:  J Neurosci       Date:  2016-07-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.